MRNA Earnings

MRNA reported its earnings on 2026-02-13, showcasing a revenue of 678.00M against an estimate of 663.62M, resulting in a 2.17% surprise. The EPS was -2.11, surpassing the expected -2.6 by 18.85%. The stock experienced a 5.29% price change on the earnings day and a 23.91% change over the next five days, reflecting market reactions to the results.

Following MRNA's earnings announcement on 2026-02-13, the stock price moved by 5.29% on the day of the release. Over the subsequent five days, it saw a 23.91% change. Historically, MRNA's stock price tends to shift by an average of 7.72% in the 10 days leading up to earnings and -0.04% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MRNA's annual revenue to reach 235.15M, while the EPS is projected at -2.34. These estimates reflect recent revisions, with revenue estimates revised upward by 0.12% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MRNA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised upward by 0.12%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MRNA's stock price typically moves by 7.72% in the 10 days before its earnings and -0.04% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -2.34 and revenue of 235.15M.

The earnings call presented a mixed outlook. Financial performance showed cost reductions and a higher cash balance, but revenue guidance was narrowed. Product development updates were promising, with potential approvals and partnerships, but guidance was cautious. The Q&A highlighted optimism in certain areas but also noted management's avoidance of direct answers on key timelines and data. The combination of strong financial metrics and cautious guidance, along with strategic partnerships, suggests a neutral impact on the stock price over the next two weeks.